carvedilol has been researched along with Pulmonary Disease, Chronic Obstructive in 15 studies
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 7.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "Patients with CHF and COPD tolerated carvedilol well with no significant reversible airflow limitation, but patients with CHF and asthma tolerated carvedilol poorly." | 7.71 | Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. ( Arnold, RH; Glanville, AR; Keogh, AM; Kotlyar, E; Macdonald, PS; McCaffrey, DJ, 2002) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 6.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 5.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| "To compare the hazard of all-cause, chronic obstructive pulmonary disease (COPD) and heart failure (HF) hospitalization in carvedilol vs." | 5.27 | Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. ( Andersen, MP; Capuano, A; Enghusen-Poulsen, H; Gislason, G; Mascolo, A; Mortensen, RN; Rosano, GMC; Rossi, F; Sessa, M; Torp-Pedersen, C, 2018) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 3.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "Clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive pulmonary disease (COPD), metoprolol/bisoprolol/nebivolol should be preferred over carvedilol." | 3.91 | Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. ( Andersen, M; Capuano, A; Jensen, MT; Kragholm, K; Mascolo, A; Pagliaro, C; Rafaniello, C; Rasmussen, DB; Rossi, F; Sessa, M; Sportiello, L; Tari, GM, 2019) |
| "Patients with CHF and COPD tolerated carvedilol well with no significant reversible airflow limitation, but patients with CHF and asthma tolerated carvedilol poorly." | 3.71 | Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. ( Arnold, RH; Glanville, AR; Keogh, AM; Kotlyar, E; Macdonald, PS; McCaffrey, DJ, 2002) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 2.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| "In subjects with COPD, forced expiratory volume in 1 s was lowest with carvedilol and highest with bisoprolol (carvedilol 1." | 2.75 | Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. ( Coleman, CF; Elsik, M; Hayward, CS; Jabbour, A; Keogh, AM; Kotlyar, E; Krum, H; Macdonald, PS; Mellemkjaer, S, 2010) |
| "Patients with chronic obstructive pulmonary disease (COPD) have airflow obstruction that leads to dynamic lung hyperinflation and reduced ventilatory response to exercise." | 2.42 | Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. ( Jelic, S; Le Jemtel, TH; Sirak, TE, 2004) |
| "Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol." | 1.46 | The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. ( Chen, CY; Huang, YB; Kuo, CC; Liao, KM; Lin, TY, 2017) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 1.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| "Chronic obstructive pulmonary disease (COPD) is present in approximately one-third of all congestive heart failure (CHF) patients, and is a key cause of underprescription and underdosing of β-blockers, largely owing to concerns about precipitating respiratory deterioration." | 1.42 | Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. ( Asai, K; Furuse, E; Kubota, Y; Murai, K; Nakamura, S; Shimizu, W; Tsukada, YT, 2015) |
| "The prevalence of COPD was 39." | 1.35 | Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. ( Azevedo, A; Bettencourt, P; Lopes, R; Lourenço, P; Mascarenhas, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sessa, M | 3 |
| Mascolo, A | 2 |
| Rasmussen, DB | 2 |
| Kragholm, K | 2 |
| Jensen, MT | 2 |
| Sportiello, L | 1 |
| Rafaniello, C | 1 |
| Tari, GM | 1 |
| Pagliaro, C | 1 |
| Andersen, M | 2 |
| Rossi, F | 2 |
| Capuano, A | 2 |
| Torp-Pedersen, C | 2 |
| Syed, MP | 1 |
| Doshi, A | 1 |
| Pandey, D | 1 |
| Kate, Y | 1 |
| Harizi, R | 1 |
| Liao, KM | 1 |
| Lin, TY | 1 |
| Huang, YB | 1 |
| Kuo, CC | 1 |
| Chen, CY | 1 |
| Mortensen, RN | 1 |
| Andersen, MP | 1 |
| Rosano, GMC | 1 |
| Gislason, G | 1 |
| Enghusen-Poulsen, H | 1 |
| Jabbal, S | 1 |
| Lipworth, BJ | 1 |
| Yanagihara, K | 1 |
| Kinugasa, Y | 1 |
| Sugihara, S | 1 |
| Hirai, M | 1 |
| Yamada, K | 1 |
| Ishida, K | 1 |
| Kato, M | 1 |
| Yamamoto, K | 1 |
| Kubota, Y | 1 |
| Asai, K | 1 |
| Furuse, E | 1 |
| Nakamura, S | 1 |
| Murai, K | 1 |
| Tsukada, YT | 1 |
| Shimizu, W | 1 |
| Su, VY | 1 |
| Chang, YS | 1 |
| Hu, YW | 1 |
| Hung, MH | 1 |
| Ou, SM | 1 |
| Lee, FY | 1 |
| Chou, KT | 1 |
| Yang, KY | 1 |
| Perng, DW | 1 |
| Chen, TJ | 1 |
| Liu, CJ | 1 |
| Jabbour, A | 1 |
| Macdonald, PS | 2 |
| Keogh, AM | 2 |
| Kotlyar, E | 2 |
| Mellemkjaer, S | 1 |
| Coleman, CF | 1 |
| Elsik, M | 1 |
| Krum, H | 1 |
| Hayward, CS | 1 |
| Lainscak, M | 1 |
| Podbregar, M | 1 |
| Kovacic, D | 1 |
| Rozman, J | 1 |
| von Haehling, S | 1 |
| Stiefelhagen, P | 1 |
| Arnold, RH | 1 |
| McCaffrey, DJ | 1 |
| Glanville, AR | 1 |
| Sirak, TE | 1 |
| Jelic, S | 1 |
| Le Jemtel, TH | 1 |
| Mascarenhas, J | 1 |
| Lourenço, P | 1 |
| Lopes, R | 1 |
| Azevedo, A | 1 |
| Bettencourt, P | 1 |
1 review available for carvedilol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Bronchoconstriction; Bronchodilator Agent | 2004 |
3 trials available for carvedilol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
Topics: Adrenergic beta-1 Receptor Agonists; Aged; Bisoprolol; Carvedilol; Cause of Death; Comorbidity; Denm | 2018 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chr | 2010 |
Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2011 |
11 other studies available for carvedilol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrioventricular Block; Bisoprolol; Carvedilol | 2019 |
Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged | 2020 |
A rare case of biventricular non-compaction.
Topics: Cardiomyopathies; Carvedilol; Coronary Artery Disease; Dyspnea; Furosemide; Heart Failure; Heart Ven | 2020 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
Sensitivity of Lung Resistance and Compliance to Beta-Blocker Induced Bronchoconstriction and Long Acting Beta-Agonist Withdrawal in COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Aged; | 2018 |
Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort St | 2013 |
Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol | 2015 |
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Con | 2016 |
[COPD patients with heart failure: no concern about the beta blocker!].
Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Comorbidity; Con | 2012 |
Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Asthma; Carbazoles; Carvedilol; Chi-Square Distribution; C | 2002 |
Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cause of Death; Dose-Response Relationshi | 2008 |